Oral docetaxel plus encequidar – a phase 1 clinical trial

David Wang,Noelyn Hung,Tak Hung,Karen Eden,Wing-Kai Chan,Rudolf Kwan,Albert Qin,Cynthia Chang,Stephen Duffull,Paul Glue,Christopher Jackson

DOI: https://doi.org/10.1007/s00280-024-04674-4

2024-06-01

Cancer Chemotherapy and Pharmacology

Abstract:To determine the bioavailability, safety, and tolerability of a single dose of oral docetaxel plus encequidar (oDox + E) and compare its pharmacokinetic exposure with current standard of care IV docetaxel.

oncology,pharmacology & pharmacy